Skip to main content
Premium Trial:

Request an Annual Quote

Ambion Licenses microRNA Sequences from Rosetta Genomics

NEW YORK, Sept. 12 (GenomeWeb News) - Rosetta Genomics and Ambion have signed an agreement that will give Ambion access to Rosetta's proprietary microRNA sequences, the companies said today.

 

Under the terms of the agreement, Ambion, a developer of RNA analysis technologies, will adapt its platform to detect, quantify, and characterize proprietary microRNA sequences discovered by Rosetta, a developer of microRNA-based therapeutics and diagnostics.

 

Additional terms of the agreement were not disclosed.

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.